Ralph Wade
Family Medicine · Bountiful, UTNPI 1447256953
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 335 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 13.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,908 and has fallen 99.4% since, to $12 in 2022.
Across 335 payments — averaging $14.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$615
- AbbVie$590
- Novo Nordisk$499
- Amarin Pharma, Inc.$437
- Merck$430
- Merz North America, Inc.$269
- plus $2K from 26 others
Across 211 payments — averaging $3259.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$362K
- Romark Laboratories, LC$255K
- Eli Lilly$34K
- Sanofi US Services Inc.$17K
- Lexicon Pharmaceuticals, Inc.$10K
- Novartis$7K
- plus $2K from 1 others
What the payments were for
- Food & beverage$4,733100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 24 | $615 |
| AbbVie(2 entities) | 41 | $590 |
| Novo Nordisk | 61 | $499 |
| Amarin Pharma, Inc. | 42 | $437 |
| Merck | 36 | $430 |
| Merz North America, Inc. | 4 | $269 |
| Sanofi-aventis U.S. LLC | 22 | $255 |
| Boehringer Ingelheim | 11 | $205 |
| Lilly USA, LLC | 19 | $194 |
| Boston Scientific | 4 | $171 |
| Astellas Pharma US Inc | 10 | $153 |
| GSK | 9 | $124 |
| Biohaven Pharmaceuticals, Inc. | 5 | $109 |
| Johnson & Johnson(2 entities) | 7 | $100 |
| Vanda Pharmaceuticals Inc. | 5 | $86 |
| Pfizer | 5 | $68 |
| Amgen | 4 | $67 |
| Upsher-smith Laboratories LLC | 4 | $59 |
| Eisai Inc. | 3 | $40 |
| Novartis | 3 | $39 |
| Cranial Technologies, Inc | 2 | $29 |
| Fidia Pharma USA Inc. | 2 | $28 |
| Adlon Therapeutics L.p. | 2 | $25 |
| Nalpropion Pharmaceuticals LLC | 2 | $25 |
| Ironshore Pharmaceuticals Inc. | 1 | $24 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Tandem Diabetes Care, Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Circassia Inc. | 1 | $12 |
| Medtronic | 1 | $12 |
| Corcept Therapeutics | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$109
- BREZTRI AEROSPHERE$109
- XEOMIN$107
How this compares
$4,733 in reported general payments places this provider in the 85th percentile of 928 family medicine providers in Utah.
Other family medicine in Bountiful
- Scott EricksonBountiful$101K
- Allen FreestoneBountiful$9K
- Michael CobbleSandy$1.3M
- Thomas ClarkProvidence$332K
- Courtney NelsonLayton$190K
- David ButtersLayton$189K
- Mark CacciamaniSalt Lake City$43K
- Clint MowerLehi$41K
- Russell AndersonTooele$30K
- Kirk OdonnellSalt Lake City$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.